Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2016

View Archived Issues

Lilly initiates phase I trial of LY-3214996 alone and in combination for advanced cancers

Novel MYH7 mutation causes Laing distal myopathy

EMA grants orphan designation to Iomab-B

EMA grants PRIME access to Atara's EBV-CTL

The Medicines Company reports positive results for PCSK-9si trial

Antegrin Therapeutics and Cascadia Therapeutics merge to form Indalo Therapeutics

EMA gives orphan drug designation to gene therapy program ABO-102

Corbus Pharmaceuticals' Resunab wins European orphan drug designation for CF

Lilly to contribute cancer research data to NCI's Blood Profiling Atlas

Rational Vaccines reports results from phase I trial of HSV vaccine

Bavarian Nordic begins phase II study of RSV vaccine

Adaptimmune Therapeutics initiates phase I study of T-cell therapy in urothelial cancer

Takeda Pharmaceutical patents enteropeptidase inhibitors

Shenyang Sunshine Pharmaceutical discloses EGLN1 inhibitors

Enanta Pharmaceuticals describes FXR agonists

Norgine reports results from phase III DAYB study of Plenvu

Celon Pharma develops PI3Kdelta inhibitors

Arisan Therapeutics presents RNA polymerase inhibitors

[18F]PSMA-1007: a promising new F-18-labeled PSMA-targeting PET tracer

In vivo results of the novel PDE4D-sparing PDE4 PET radioligand [18F]PF-06445974

Phase I study shows feasibility of combining lurbinectedin and capecitabine

Leukemia & Lymphoma Society announce launch of Beat AML Master Trial

FDA approves Tecentriq for metastatic NSCLC

HiberGene announces launch of HG Group B Streptococcus direct swab test

KemPharm enters agreement with Acura Pharmaceuticals for Aversion technology

Spero Therapeutics receives DoD award for anti-infective potentiator program

Novel targeted alpha radiotherapeutic shows potential for prostate cancer

ContraVir Pharmaceuticals begins enrollment of next dosing group in phase IIa trial of CMX-157

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...